Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
Antonioli, Elisabetta, Pilerci, Sofia, Attucci, Irene, Buda, Gabriele, Gozzetti, Alessandro, Candi, Veronica, Simonetti, Federico, Giudice, Maria Livia Del, Ciofini, Sara, Staderini, Michela, Grammatico, Sara, Buzzichelli, Alessandra, Messeri, Maria, Bocchia, Monica, Galimberti, Sara, Vannucchi, Alessandro M
Published in Frontiers in oncology (25.04.2023)
Published in Frontiers in oncology (25.04.2023)
Get full text
Journal Article
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience
Antonioli, Elisabetta, Staderini, Michela, Pilerci, Sofia, Perfetto, Federico, Cappelli, Francesco, Allinovi, Marco, Nozzoli, Chiara, Attucci, Irene, Buzzichelli, Alessandra, Messeri, Maria, Bosi, Alberto
Published in Leukemia & lymphoma (09.11.2020)
Published in Leukemia & lymphoma (09.11.2020)
Get full text
Journal Article
Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study
Attardi, Enrico, Pilerci, Sofia, Attucci, Irene, Buzzichelli, Alessandra, Messeri, Maria, Staderini, Michela, Vannucchi, Alessandro M, Antonioli, Elisabetta
Published in Clinical lymphoma, myeloma and leukemia (01.11.2021)
Published in Clinical lymphoma, myeloma and leukemia (01.11.2021)
Get full text
Journal Article
Safety of rapid daratumumab infusion in relapsed and refractory multiple myeloma
Antonioli, Elisabetta, Attardi, Enrico, Staderini, Michela, Nozzoli, Chiara, Buzzichelli, Alessandra, Messeri, Maria, Bosi, Alberto
Published in Clinical lymphoma, myeloma and leukemia (01.10.2019)
Published in Clinical lymphoma, myeloma and leukemia (01.10.2019)
Get full text
Journal Article